Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469686 | 1.00 | TSHR (0.43) | TSHRLMNAMETAP1ALDH1A1OPRM1 | |
| SCHEMBL1307930 | 0.88 | TSHR (0.35) | TSHRALDH1A1TDP1ALOX15 | |
| SCHEMBL19511846 | 0.85 | TSHR (0.43) | TSHRLMNAMETAP1ALDH1A1CHRM1 | |
| SCHEMBL599955 | 0.85 | TSHR (0.40) | TSHRLMNAMETAP1OPRM1CHRM1 | |
| SCHEMBL727213 | 0.84 | ALDH1A1 (0.41) | TSHRLMNAALDH1A1OPRM1SMN1; SMN2 | |
| SCHEMBL980782 | 0.84 | ALDH1A1 (0.41) | TSHRLMNAMETAP1ALDH1A1CHRM1 | |
| SCHEMBL15469680 | 0.84 | ALDH1A1 (0.41) | TSHRLMNAALDH1A1OPRM1SMN1; SMN2 | |
| SCHEMBL18124681 | 0.84 | ALDH1A1 (0.41) | TSHRLMNAALDH1A1OPRM1SMN1; SMN2 | |
| SCHEMBL17715618 | 0.81 | TSHR (0.42) | TSHRLMNAMETAP1ALDH1A1TDP1 | |
| SCHEMBL23115448 | 0.80 | LMNA (0.48) | TSHRLMNAALDH1A1OPRM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688838-B1 | Diisononyl terephthalate plasticizer and its use as well as process for producing the same | NAN YA PLASTICS CORPORATION (TW) | 2017-06-27 | — | — | US | claimed |
| EP-3027760-A1 | PROCESS FOR THE BIOCONVERSION OF C3-C13 ALKANES TO C3-C 13 PRIMARY ALCOHOLS | BASF SE (DE) | 2016-06-08 | — | — | EP | claimed |
| WO-2015014644-A1 | PROCESS FOR THE BIOCONVERSION OF C3-C13 ALKANES TO C3-C 13 PRIMARY ALCOHOLS | BASF SE (DE) | 2015-02-05 | — | — | WO | claimed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-11 | — | — | US | disclosed |
| US-20230140047-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-04 | — | — | US | disclosed |
| US-20230127326-A1 | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-10420767-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-09-24 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-06-07 | — | — | US | disclosed |
| US-9416114-B2 | 1,2,4-triazine derivatives for the treatment of viral infections | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-16 | — | — | US | disclosed |
| US-9416114-B2 | 1,2,4-triazine derivatives for the treatment of viral infections | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-16 | — | — | US | disclosed |
| US-20160016966-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20150336907-A1 | 1,2,4-TRIAZINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | UNIVERSITE DE ROUEN (FR) | 2015-11-26 | — | — | US | disclosed |
| US-20150336907-A1 | 1,2,4-TRIAZINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | UNIVERSITE DE ROUEN (FR) | 2015-11-26 | — | — | US | disclosed |
| US-9085582-B2 | Benzotriazolodiazepine compounds inhibitors of bromodomains | GLAXOSMITHKLINE LLC (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127326-A1 | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR3, TLR9 | TSHR 866/4885LMNA 3326/4885METAP1 2095/4885 |
| US-20230140047-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | TLR7, TLR1, TLR9 | TSHR 2021/4885LMNA 3881/4885METAP1 1669/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | TSHR 4783/4885LMNA 2444/4885METAP1 477/4885 |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | TSHR 3940/4885LMNA 3513/4885METAP1 3574/4885 |
| US-20150336907-A1 | 1,2,4-TRIAZINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | MAVS, IL5, ZC3HAV1 | TSHR 2857/4885LMNA 3735/4885METAP1 1243/4885 |
| US-10420767-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | TSHR 4335/4885LMNA 3150/4885METAP1 1887/4885 |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | TSHR 2900/4885LMNA 4684/4885METAP1 3041/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | TSHR 2606/4885LMNA 4638/4885METAP1 3469/4885 |
| US-20160016966-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | BRD3, BRD4, BRPF3 | TSHR 3116/4885LMNA 3291/4885METAP1 1541/4885 |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | PNP, UMPS, UPP1 | TSHR 3467/4885LMNA 2578/4885METAP1 916/4885 |
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | TSHR 1285/4885LMNA 3915/4885METAP1 2862/4885 |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TSHR 4335/4885LMNA 3150/4885METAP1 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.